v3.25.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Cash flows from operating activities:    
Net loss from continuing operations $ (23,258) $ (29,537)
Adjustments to reconcile net loss to net cash used in operating activities:    
Gain on sale of patents (3,000) 0
Stock-based compensation 2,904 3,958
Depreciation and amortization 2,596 3,779
Reversal of uncertain tax positions (261) (81)
Deferred income tax expense (benefit) (38) 101
Loss on asset disposal 36 0
Changes in operating assets and liabilities:    
Accounts receivable, net 1,323 4,271
Inventories 726 (242)
Prepaid expenses and other current and long-term assets, net 2,486 4,810
Accounts payable (680) (1,016)
Accrued current and long-term liabilities (3,434) (6,081)
Income taxes payable (6) 231
Net cash used in operating activities (20,606) (19,807)
Cash flows from investing activities:    
Proceeds from sale of patents 3,000 0
Asset related government subsidies received 754 641
Purchases of property and equipment (448) (3,760)
Net cash provided by (used in) investing activities 3,306 (3,119)
Cash flows from financing activities:    
Proceeds from issuance of common stock 7,882 0
Net proceeds from "at the market" equity offering 2,952 157
Proceeds from Lines of Credit 2,145 0
Payments on asset financings (1,307) (1,308)
Proceeds from issuances of common stock under employee equity incentive plans 48 180
Net cash provided by (used in) financing activities 11,720 (971)
Net decrease in cash and cash equivalents (5,580) (23,897)
Cash and cash equivalents, beginning of period 23,647 47,544
Cash and cash equivalents, end of period 18,067 23,647
Supplemental disclosure of cash flow information:    
Cash paid for income taxes, net of refunds received 552 227
Cash paid during the year for interest 127 97
Non-cash investing and financing activities:    
Purchases of property and equipment and other assets under extended payment terms $ 6 $ 517